

d his

(FILE 'HOME' ENTERED AT 09:04:21 ON 27 JUL 2003)

FILE 'CAPLUS' ENTERED AT 09:04:29 ON 27 JUL 2003

L1 0 S CARBOHYDRATES FOR FACILITATING THE TRANSPOR?  
L2 0 S CARBOHYDRATES FOR ENHANC? THE TRANSPOR?  
L3 2 S CARBOHYDRATES FOR ENHANC? THE ABSORPTION  
L4 5 S ?SACCHARID? FOR ENHANC? THE ABSORPTION  
L5 3 S ?SACCHARID? FOR PROMOT? THE ABSORPTION  
L6 0 S ?SACCHARID? W ABSORPTION  
L7 0 S ?SACCHARID? W6 ABSORPTION  
L8 0 S ?SACCHARID? ADJ6 ABSORPTION  
L9 0 S ?SACCHARID? ADJ6 ABSORPTION ADJ6 AMINO ACID?  
L10 0 S ?CARBOHYDRAT? ADJ6 ABSORPTION ADJ6 AMINO ACID?  
L11 0 S CARBOHYDRAT? ADJ6 ABSORPTION ADJ6 AMINO ACID?  
L12 0 S CARBOHYDRAT? ABSORPTION AMINO ACID?  
L13 0 S ?SACCHARID? FOR ENHANC? THE TRANSPOR?  
L14 0 S ?SACCHARID? FOR INCREAS? THE TRANSPOR?  
L15 0 S ?SACCHARID? INCREAS? THE TRANSPOR?  
L16 3 S ?SACCHARID? INCREAS? THE ABSORPTION?  
L17 3 S CARBOYDRAT? AND AMINO ACI?  
L18 31 S CARBOYDRAT?  
L19 183232 S CARBOHYDRAT?  
L20 24450 S L19 AND AMINO ACI?  
L21 8387 S L20 AND COMPOSITION  
L22 2 S L21 AND TREATING DISORD?  
L23 0 S L21 AND TREATING ADJ4 DISORD?  
L24 80 S L21 AND TREATING  
L25 0 S L24 AND EPITHEL?  
L26 4 S L24 AND GASTRO?  
L27 34 S L24 AND DISEAS?

L42 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:511689 CAPLUS  
DOCUMENT NUMBER: 127:126668  
TITLE: Macromolecular prodrugs of nucleotide analogs  
INVENTOR(S): Josephson, Lee; Groman, Ernest V.; Wu, Yong-Qian  
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., USA  
SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9721452	A2	19970619	WO 1996-US19794	19961212
WO 9721452	A3	19971009		
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5981507	A	19991109	US 1996-766597	19961212
PRIORITY APPLN. INFO.:			US 1995-8600P	P 19951214
			US 1996-27325P	P 19961003
			US 1996-28331P	P 19961011

AB An antiviral or anticancer pharmaceutical **compn.** comprises conjugates of dextran or starch derivs. with antiviral heterocyclic derivs. of adenine, cytosine, thymine, or guanine. Examples of nucleoside analogs include **acyclovir**, ribavirin, AZT or ara C. Among many examples given, a carboxymethyl dextran-ethylenediamine-deoxyfluorouridine phosphate conjugate was prepd. The effect of macromol. prodrugs on HBV replication was also given.

L42 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN.

ACCESSION NUMBER: 1997:511689 CAPLUS  
DOCUMENT NUMBER: 127:126668  
TITLE: Macromolecular prodrugs of nucleotide analogs  
INVENTOR(S): Josephson, Lee; Groman, Ernest V.; Wu, Yong-Qian  
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., USA  
SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9721452	A2	19970619	WO 1996-US19794	19961212
WO 9721452	A3	19971009		
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5981507	A	19991109	US 1996-766597	19961212
PRIORITY APPLN. INFO.:			US 1995-8600P	P 19951214
			US 1996-27325P	P 19961003
			US 1996-28331P	P 19961011

AB An antiviral or anticancer pharmaceutical **compn.** comprises conjugates of dextran or starch derivs. with antiviral heterocyclic derivs. of adenine, cytosine, thymine, or guanine. Examples of nucleoside analogs include **acyclovir**, ribavirin, AZT or ara C. Among many examples given, a carboxymethyl dextran-ethylenediamine-deoxyfluorouridine phosphate conjugate was prepd. The effect of macromol. prodrugs on HBV replication was also given.

L42 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:490947 CAPLUS  
DOCUMENT NUMBER: 139:74009  
TITLE: Controlled release pharmaceuticals containing  
polymer-bound drugs  
INVENTOR(S): Corcoran, Robert C.  
PATENT ASSIGNEE(S): The University of Wyoming, USA  
SOURCE: PCT Int. Appl., 118 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051113	A1	20030626	WO 2002-US40207	20021216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-341153P P 20011214

AB This invention provides a method and **compos.** for the controlled release of drugs that have been attached by means of a covalent bond to a polymer or other moiety that blocks activity of the drug until it has been released. A 2-stage process is provided in which an unmasking reaction results in the formation of a chem. group that can then undergo a second reaction to release the drug. Thus, the narcotic analgesic fentanyl covalently attached to an inert polymer by way of its nitrogen through the formation of a quaternary vinylammonium salt, and then released by a sequence involving hydrolysis of an acetal that exposes an alc. that may then undergo an intramol. nucleophilic substitution reaction involving displacement of the nitrogen of oxycodone. The rate of this process may be controlled by controlling either or both of the rates of the acetal hydrolysis or the intramol. substitution reaction, but is preferably controlled by the latter through varying the no. of atoms in the chain connecting the alc. group and the vinylic carbon, as well as by the addn. of substituents on that chain. The drug-delivery mols. of this invention are useful for release of amine, alc. and thiol drugs, including a no. of narcotic analgesics, tricyclic amine antidepressants, and many others.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:154224 CAPLUS  
DOCUMENT NUMBER: 138:193294  
TITLE: Expandable gastric retention device containing  
pharmaceutical **compositions**  
INVENTOR(S): Ayres, James W.  
PATENT ASSIGNEE(S): The State of Oregon Acting by and Through the State  
Board of Higher Education On Behalf of Oregon State  
University, USA  
SOURCE: PCT Int. Appl., 110 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015745	A1	20030227	WO 2001-US46146	20011022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-313078P P 20010816

AB The present application concerns gastric retention devices formed from **compsn.** comprising polymeric materials, such as **polysaccharides**, and optional addnl. materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time. Dry powders of xanthan gum and locust bean gum were mixed intimately were converted to dried films. The dried films were compressed with the help of specially made punches and dies. A series of dies with decreasingly narrow internal diams. were used. A punch pushes the film from one die into the next die, followed by pushing of the film by another punch into the next die. This process takes place in succession until a point is reached where the film is small enough to put into a desired capsule size.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:1215 CAPLUS

DOCUMENT NUMBER: 138:61315

TITLE: Controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers

INVENTOR(S): Chhabra, Harinderpal; Sarkar, Shyamal K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 23 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500459	B1	20021231	US 1999-358732	19990721

PRIORITY APPLN. INFO.: US 1999-358732 19990721

AB A pharmaceutical **compn.** for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 soln. in iso-PROH (30% wt./wt.). The wet mass obtained in the above step was dried at 60.degree. for 3 h. After drying, the granules were passed a mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The

granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a wt. gain of 1.66% of the wt. of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:794310 CAPLUS

DOCUMENT NUMBER: 137:284401

TITLE: Universal antiviral **compositions** containing acidic buffer and wound healing agent

INVENTOR(S): Burke, Peter A.; Coulter, Stephen L.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U. S. Ser. No. 281,391.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002151521	A1	20021017	US 2001-903289	20010711

PRIORITY APPLN. INFO.: US 1999-281391 A2 19990330

AB There is provided an universal antiviral **compn.** in the form of a lotion, foam or gel that is non-irritating. The **compn.** contains an effective antimicrobicidal agent, an acidic buffer and wound healing agent so that the pH is 7. The **compn.** of the invention can be used in connection with packaged. A topical lotion contained propylene glycol stearate 9.50, isocetyl alc. 5.00, PEG-100 stearate 1.20, hyaluronic acid 2.00, methylparaben 0.20, propylene glycol 13.10, sorbitan palmitate 0.60, Octoxynol-9 6.00 Mate ext. 0.50, and water qs 100%.

L42 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:706380 CAPLUS

DOCUMENT NUMBER: 138:29114

TITLE: Antiviral pharmaceutical **composition**

PATENT ASSIGNEE(S): Otkrytoe Aktsionernoe Obshchestvo Khimiko-Farmatsevticheskii Kombinat "Akrikhin", Russia

SOURCE: Russ., No pp. given

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2179851	C1	20020227	RU 2000-131938	20001221

PRIORITY APPLN. INFO.: RU 2000-131938 20001221

AB The method suggested contains, g/100 mL: **acyclovir** as an active substance 0.1-20.0 and a cellulose deriv. as addnl. substances 0.1-15.0, mono- or **disaccharide** or the mixt. of mentioned sugars 112.0-65.0, alc. 0.5-45.0, water - up to 100 mL and conservant 0-3.0, not obligatory. The **compn.** may addnl. contain an aromatizer at 0.1-5.0 g/100 mL **compn.** The novel pharmaceutical **compn.** is obtained by applying usual methods in the form of a suspension. The **compn.** in question meets the requirements for pharmaceutical

prepn. being stable at storage period. The prepn. exhibits higher antiviral efficiency and stability at storage period.

L42 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:657934 CAPLUS

DOCUMENT NUMBER: 137:206536

TITLE: Cubic liquid crystalline **compositions** and methods for their preparation

INVENTOR(S): Spicer, Patrick Thomas; Small, William Broderick, II; Lynch, Matthew Lawrence

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002066014	A2	20020829	WO 2002-US4776	20020219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002160040	A1	20021031	US 2001-990552	20011121
PRIORITY APPLN. INFO.:			US 2001-269953P P	20010220
			US 2001-990552 A	20011121

AB A dry powder cubic gel precursor comprising an encapsulating compd., an amphiphile capable of forming a cubic liq. cryst. phase, and optionally a solvent is described. The encapsulating compd. (A), amphiphile (B), and optional solvent (C) are present in mass fractions relative to each other such that  $1.0 = a + b + c$ , wherein  $a$  is the mass fraction of A,  $b$  is the mass fraction of B, and  $c$  is the mass fraction of C. Further,  $1.0 > a > 0$ ,  $1.0 > b > 0$ ,  $1.0 > c > 0$  and  $a$ ,  $b$ , and  $c$  do not fall within a cubic liq. cryst. phase region on a phase diagram representing phase behavior of A, B, and C. A method of making the cubic gel precursor comprises the steps of: (i) dissolving an encapsulating compd. in a solvent; (ii) adding an amphiphile; (iii) mixing the encapsulating compd. and amphiphile, wherein steps (i), (ii), and (iii) are performed in any order; (iv) atomizing the mixt. obtained; and, (v) drying the mixt. For example, an active ingredient (fatty acid soln.) was encapsulated in powders made by spray-drying a liq. soln. The liq. soln. was prepd. from a premix of 67% water and 33% starch at 70.degree.. A second soln. of 90% monoolein and 10% fatty acid mix (20% omega-3, 80% triglyceride oil) was prepd. at 60.degree.. The oil soln. was then added to the starch-water soln. forming a 9% monoolein, 30% starch, 60% water, and 1% fatty acid mixt. A high shear mixing system was used to keep the system mixed and maintained above 90.degree.. The mixt. was then pumped at a rate of 8 mL/min through the liq. side of a twin-fluid atomizer, with slight adjustments being made to the flow rate to keep the temp. of the exit air in the system between 90-100.degree.. The liq. feed was atomized with air at a pressure of 42.6 psi (293.5 kPa). Upon drying, the powder has a **compn.** of 22.5% monoolein, 75% starch, and 2.5% fatty acid mixt. The powder appears to exhibit a bimodal size distribution of larger 10 .mu.m particles and smaller 3-5 .mu.m particles, all of which exhibit the classical shrinkage that is characteristic of starch capsules during their cooling. The uniform appearance of the powders can be an excellent indicator that the fatty acid active is encapsulated within the starch shells.

L42 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:521933 CAPLUS

DOCUMENT NUMBER: 137:108286

TITLE: Antibodies and fragments against epitopes present on cancer, metastatic or leukemia cells and platelets for diagnosis and therapy of tumor, metastasis, leukemia, autoimmune disease, and inflammation

INVENTOR(S): Lazarovits, Janette; Hagai, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Kooperman, Lena; Peretz, Tuvia; Levanon, Avigdor

PATENT ASSIGNEE(S): Bio-Technology General Corp., USA

SOURCE: PCT Int. Appl., 310 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053700	A2	20020711	WO 2001-US49442	20011231
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-258948P P 20001229

US 2000-751181 A 20001229

AB The present invention provides epitopes present on cancer cells and important in physiolo. phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and **compns**. using antibodies capable of binding to the epitopes are provided. The antibodies or fragments are capable of binding to, e.g. PSGL-1, fibrinogen .gamma. prime, GPIIb.alpha., heparin, lumican, complement compd. 4 (CC4), interalpha inhibitor and prothrombin. Methods and **compns**. according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease.

L42 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:185616 CAPLUS

DOCUMENT NUMBER: 136:252482

TITLE: Preparation of aqueous clear solution dosage forms with bile acids

INVENTOR(S): Yoo, Seo Hong

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002031558	A1	20020314	US 2001-778154	20010205
US 6251428	B1	20010626	US 1999-357549	19990720



## PRIORITY APPLN. INFO.:

US 1998-94069P P 19980724  
US 1999-357549 A2 19990720  
US 2000-180268P P 20000204

AB **Compns.** for pharmaceutical and other uses comprise clear aq. solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aq. soln. The **compns.** comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aq. sol. starch conversion product and an aq. sol. non-starch **polysaccharide**. The **compn.** remains in soln. without forming a ppt. over a range of pH values and, according to one embodiment, remains in soln. for all pH values obtainable in an aq. system. The **compn.** may further contain a pharmaceutical compd., such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, soln. dosage forms that did not show any pptn. at any pH were prepd. contg. ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

L42 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:182217 CAPLUS

DOCUMENT NUMBER: 136:236843

TITLE: Polymer-based matrixes for wound dressing devices containing antimicrobial agents

INVENTOR(S): Gibbins, Bruce L.

PATENT ASSIGNEE(S): AcryMed, Inc., USA

SOURCE: U.S., 14 pp., Cont.-in-part of U.S. 5,928,174.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6355858	B1	20020312	US 1998-191223	19981113

## PRIORITY APPLN. INFO.:

US 1997-971074 A2 19971114

AB The present invention comprises methods and **compns.** for treating wounds. More particularly, the present invention comprises methods and **compns.** for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable **polysaccharide** having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for the treatment of wounds. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1.times.10<sup>6</sup> units of penicillin G powder into 50 mL water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixt. were mixed for 2 h. The penicillin soln. was then added to an aq. soln. of TEMED and after thorough mixing, ammonium persulfate in water was added and mixed thoroughly. The mixt. was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Prior to testing, the sheets were placed in a humidified environment until the sheet wt. had increased to approx. 118-122% the storage wt. Disks were cut and placed onto the surfaces of agar plates that had previously been seeded with various strains of microorganisms (Staphylococcus aureus; Escherichia coli; Candida albicans; Pseudomonas aeruginosa). Zones of inhibition were measured around the penicillin contg. matrix but not the control matrix on the S. aureus, E. coli, and P. aeruginosa plates. The results demonstrated the release of active penicillin G after its incorporation into the matrix.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:581685 CAPLUS  
DOCUMENT NUMBER: 135:157683  
TITLE: Preparation of aqueous clear solution dosage forms  
with bile acids  
INVENTOR(S): Yoo, Seo Hong  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056547	A2	20010809	WO 2001-US3745	20010205
WO 2001056547	A3	20020718		
WO 2001056547	B1	20030220		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1255566	A2	20021113	EP 2001-908862	20010205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2000-180268P P 20000204  
WO 2001-US3745 W 20010205

AB **Compns.** for pharmaceutical and other uses comprising clear aq. solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aq. soln. and methods of making such solns. The **compns.** of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aq. sol. starch conversion product and a aq. sol. non-starch **polysaccharide**. The **compn.** remains in soln. without forming a ppt. over a range of pH values and, according to one embodiment, remains in soln. for all pH values obtainable in an aq. system. The **compn.**, according to some embodiments, may further contain a pharmaceutical compd. in a pharmaceutically effective amt. Non-limiting examples of pharmaceutical compds. include insulin, heparin, bismuth compds., amantadine and rimantadine. A syrup **compn.** contained ursodeoxycholic acid 20 g, 1N NaOH 60 mL, corn syrup solid 1050 g, Bi citrate 4g, citric acid or lactic acid q.s. and purified water to 1L.

L42 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:396644 CAPLUS  
DOCUMENT NUMBER: 135:24671  
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical **compositions**  
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing  
PATENT ASSIGNEE(S): Lipocine, Inc., USA  
SOURCE: PCT Int. Appl., 107 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 8  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003517470	T2	20030527	JP 2001-539423	20001122
PRIORITY APPLN. INFO.:			US 1999-447690	A 19991123
			WO 2000-US32255	W 20001122

AB The present invention provides solid pharmaceutical **compns.** for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical **compn.** includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical **compn.** includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The **compns.** of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A **compn.** contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:300514 CAPLUS  
 DOCUMENT NUMBER: 134:331617  
 TITLE: Oil-in-water emulsion **compositions** for polyfunctional active ingredients  
 INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 2002107265 A1 20020808 US 1999-420159 19991018  
 PRIORITY APPLN. INFO.: US 1999-420159 A 19991018  
 AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aq. phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepd., with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The **compn.** contained (by wt.) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:31287 CAPLUS  
 DOCUMENT NUMBER: 134:105670  
 TITLE: Pharmaceutical and cosmetic **compositions** containing **oligosaccharide** aldonic acids and their topical use  
 INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: PCT Int. Appl., 86 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001932	A2	20010111	WO 2000-US16301	20000628
WO 2001001932	A3	20010517		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6335023	B1	20020101	US 2000-487228	20000119
BR 2000011640	A	20020514	BR 2000-11640	20000628
EP 1227820	A2	20020807	EP 2000-950220	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503436	T2	20030128	JP 2001-507430	20000628
US 2002028227	A1	20020307	US 2001-987023	20011113
PRIORITY APPLN. INFO.: US 1999-141264P P 19990630				
US 2000-487228 A 20000119				
WO 2000-US16301 W 20000628				

OTHER SOURCE(S): MARPAT 134:105670  
 AB **Compns.** comprising **oligosaccharide** aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those assocd. with intrinsic and/or extrinsic aging, as well as with changes or

damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. **Compns.** comprising **oligosaccharide** aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepd. by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

L42 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:68148 CAPLUS

DOCUMENT NUMBER: 132:113102

TITLE: **Composition** and pharmaceutical dosage form for colonic drug delivery using **polysaccharides**

INVENTOR(S): Lee, Seung Seo; Lim, Chang Baeg; Pai, Chaul Min; Lee, Sujung; Park, In; Seo, Moon Gun; Park, Heenam

PATENT ASSIGNEE(S): Samyang Corporation, S. Korea

SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974344	A2	20000126	EP 1999-305600	19990715
EP 974344	A3	20000301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
KR 2000011247	A	20000225	KR 1999-14665	19990423
CA 2336815	AA	20000203	CA 1999-2336815	19990520
WO 2000004924	A1	20000203	WO 1999-KR250	19990520
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9940627	A1	20000214	AU 1999-40627	19990520
AU 744183	B2	20020214		
JP 2002521346	T2	20020716	JP 2000-560917	19990520
US 6413494	B1	20020702	US 1999-318579	19990525
PRIORITY APPLN. INFO.:			KR 1998-29740	A 19980723
			KR 1999-14665	A 19990423
			WO 1999-KR250	W 19990520

AB A colonic drug delivery **compn.** contains a first **polysaccharide** and a second **polysaccharide** wherein both **polysaccharides** are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above. A colon selective pharmaceutical **compn.** and dosage form for oral delivery of a drug, nutrient, diagnostic reagent, or mixt. thereof includes the drug, nutrient, diagnostic reagent, or mixt. thereof in contact with the **polysaccharide compn.** A method of prepg. such a colonic drug delivery **compn.** and the colon selective pharmaceutical **compn.** and dosage form are also disclosed. Capsules filled with budesonide pellets were coated with a **compn.** contg. pectin and guar gum at the ratio of 4 to 1 (pH 8), to a thickness of 15 mg/cm<sup>2</sup>. The capsules were disintegrated in 60 min in simulated colonic fluid, but not disintegrated in simulated gastric or intestinal fluid during 24 h

studies.

L42 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:350613 CAPLUS  
DOCUMENT NUMBER: 130:357215  
TITLE: Improved wound dressing device and methods  
INVENTOR(S): Gibbins, Bruce L.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925395	A2	19990527	WO 1998-US24272	19981113
WO 9925395	A3	19990812		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9916991	A1	19990607	AU 1999-16991	19981113
EP 1030695	A2	20000830	EP 1998-961733	19981113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRIORITY APPLN. INFO.: US 1997-971074 A2 19971114  
WO 1998-US24272 W 19981113

AB The present invention comprises methods and **compns.** for treating wounds. More particularly, the present invention comprises methods and **compns.** for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable **polysaccharide** having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of wounds. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg guar gum was dispersed in a mixt. contg. 0.9770 kg isopropanol and 2 kg water. The soln. of guar gum was dispersed into the acrylamide mixt. After suitable mixing, 0.1042 kg TEMED was added and polymn. was catalyzed with 0.0999 kg ammonium persulfate. While the batch was still liq., it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.

L42 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:21715 CAPLUS  
DOCUMENT NUMBER: 130:100712  
TITLE: Bioresorbable **compositions** for implantable prostheses  
INVENTOR(S): Loomis, Gary L.  
PATENT ASSIGNEE(S): Meadox Medicals, Inc., USA  
SOURCE: U.S., 8 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 5854382	A	19981229	US 1997-914130	19970818
CA 2303807	AA	19990225	CA 1998-2303807	19980814
WO 9908718	A2	19990225	WO 1998-US16933	19980814
WO 9908718	A3	19990520		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1019096	A2	20000719	EP 1998-938491	19980814
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2001514931	T2	20010918	JP 2000-509454	19980814
US 6005020	A	19991221	US 1998-145588	19980902
US 6028164	A	20000222	US 1999-243379	19990201
US 6316522	B1	20011113	US 1999-395725	19990914
US 6403758	B1	20020611	US 1999-436774	19991108
US 2002035168	A1	20020321	US 2001-957427	20010920
US 6534560	B2	20030318		

PRIORITY APPLN. INFO.:

US 1997-914130	A	19970818
WO 1998-US16933	W	19980814
US 1998-145588	A1	19980902
US 1999-243379	A2	19990201
US 1999-395725	A1	19990914

AB Crosslinked **compns.** formed from a water-insol. copolymer are disclosed. These **compns.** are copolymers having a bioresorbable region, a hydrophilic region and at least two crosslinkable functional groups per polymer chain. These **compns.** are able to form hydrogels in aq. environments when crosslinked. These hydrogels are good sealants for implantable prostheses when in contact with an aq. environment. In addn., such hydrogels can be used as delivery vehicles for therapeutic agents. An aq. emulsion was prepd. by dispersing ethylene oxide-propylene oxide-lactide block copolymer acrylate and Vazo 044. A knitted polyester medical fabric was impregnated by immersing it in the above emulsion and dried to give a porous coating.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:789030 CAPLUS

DOCUMENT NUMBER: 130:43296

TITLE: Immunomodulating, bile-derivable **compositions** for the treatment of viral disorders

INVENTOR(S): Percheson, Paul

PATENT ASSIGNEE(S): Imutec Pharma Inc., Can.

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852585	A1	19981126	WO 1998-CA494	19980522

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2238460 AA 19981123 CA 1998-2238460 19980522  
AU 9875160 A1 19981211 AU 1998-75160 19980522  
ZA 9806224 A 19990429 ZA 1998-6224 19980713

PRIORITY APPLN. INFO.: CA 1997-2206047 A 19970523  
WO 1998-CA494 W 19980522

OTHER SOURCE(S): MARPAT 130:43296

AB The present invention relates to the use of a **compn.** exhibiting antiviral properties, comprising small mol. wt. components of less than 3000 daltons, and having the following properties: (a) is extractable from bile of animals; (b) is capable of stimulating monocytes and macrophages in vitro and in vivo; (c) is capable of modulating tumor necrosis factor prodn.; (d) contains no measurable IL-1.alpha., IL-1.beta., TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-.gamma.; (e) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and (f) is not an endotoxin. The invention also relates to the use of the antiviral **compn.** when used in conjunction with other drugs such as antiviral compds. or immunomodulators such as interferon.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:708921 CAPLUS

DOCUMENT NUMBER: 129:347286

TITLE: A bioadhesive drug delivery system based on liquid crystals

INVENTOR(S): Nielsen, Lise Sylvest

PATENT ASSIGNEE(S): Dumex-Alpha A/S, Den.

SOURCE: PCT Int. Appl., 176 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847487	A1	19981029	WO 1998-DK159	19980417
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, EE, ES, FI, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

AU 9869195 A1 19981113 AU 1998-69195 19980417

EP 975331 A1 20000202 EP 1998-914850 19980417

R: CH, DE, DK, ES, FR, GB, IT, LI, NL

JP 2001524958 T2 20011204 JP 1998-544757 19980417

PRIORITY APPLN. INFO.: DK 1997-435 A 19970417

WO 1998-DK159 W 19980417

AB A drug delivery system contg. a liq. cryst. phase such as a cubic, a hexagonal, a reverse hexagonal, a lamellar, a micellar and a reverse micellar liq. cryst. phase is disclosed. The **compns.** are unique in that they, as delivery systems, contain A) a substance which is capable of generating a liq. cryst. phase and providing suitable biopharmaceutical properties like e.g. suitable release of the active substance and bioadhesive properties, and B) at least another substance which without having any substantially neg. effect on the biopharmaceutical properties provided by the substance mentioned above under A) either takes part in



the formation of a liq. cryst. phase or dils. the proportion of liq. cryst. phase in the **compn.** while still maintaining suitable biopharmaceutical properties and a suitable storage stability. Examples of substances A) are fatty acid esters like e.g. glycerylmonooleate and glycerylmonolinoleate and examples of substances B) are e.g. structurants like phospholipids and tocopherols and/or pharmaceutically acceptable excipients.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:706082 CAPLUS

DOCUMENT NUMBER: 129:335760

TITLE: Molecular complex and controlled-release of .alpha.-hydroxy acids

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846217	A1	19981022	WO 1998-US7073	19980410
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5877212	A	19990302	US 1997-842603	19970416
AU 9868939	A1	19981111	AU 1998-68939	19980410
AU 734741	B2	20010621		
EP 1009398	A1	20000621	EP 1998-914628	19980410
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001520652	T2	20011030	JP 1998-544038	19980410
BR 9808928	A	20011204	BR 1998-8928	19980410
MX 9909504	A	20000831	MX 1999-9504	19991015
PRIORITY APPLN. INFO.:			US 1997-842603 A2	19970416
			WO 1998-US7073 W	19980410

AB **Compns.** comprising an .alpha.-hydroxy acid or related acid and org. complexing agent having a mol. wt. ranging preferably between about 100 and about 600 can form a controlled-release mol. complex. Such complexing agents preferably have 1 or more amino groups in addn. to other groups with unshared electrons such as OH, carbonyl, amido, ester and alkoxyl groups in the same mol. Such functional groups are capable of forming multiple intermol. hydrogen bonds with the OH groups of a free .alpha.-hydroxy acid or related acid. The complexing agents include amino acid esters, non-amphoteric amino acid amides, **aminosaccharides**, aminoalditols and aminocyclitols. A cream contained 7.6% glycolic acid and 5.2% glycine Et ester in a molar ratio of 2:1. The **compn.** reduced skin disorders like wrinkles, acne, etc.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:511689 CAPLUS

DOCUMENT NUMBER: 127:126668

TITLE: Macromolecular prodrugs of nucleotide analogs  
 INVENTOR(S): Josephson, Lee; Groman, Ernest V.; Wu, Yong-Qian  
 PATENT ASSIGNEE(S): Advanced Magnetics, Inc., USA  
 SOURCE: PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721452	A2	19970619	WO 1996-US19794	19961212
WO 9721452	A3	19971009		
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5981507	A	19991109	US 1996-766597	19961212
PRIORITY APPLN. INFO.:			US 1995-8600P	P 19951214
			US 1996-27325P	P 19961003
			US 1996-28331P	P 19961011

AB An antiviral or anticancer pharmaceutical **compn.** comprises conjugates of dextran or starch derivs. with antiviral heterocyclic derivs. of adenine, cytosine, thymine, or guanine. Examples of nucleoside analogs include **acyclovir**, ribavirin, AZT or ara C. Among many examples given, a carboxymethyl dextran-ethylenediamine-deoxyfluorouridine phosphate conjugate was prepd. The effect of macromol. prodrugs on HBV replication was also given.

L42 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:356544 CAPLUS  
 DOCUMENT NUMBER: 126:334374  
 TITLE: A pharmaceutical **composition** for administration of an active substance to or through skin or mucosal surface  
 INVENTOR(S): Nielsen, Lise Sylvest; Hansen, Jens  
 PATENT ASSIGNEE(S): Dumex-Alpha A/s, Den.; Nielsen, Lise Sylvest; Hansen, Jens  
 SOURCE: PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9713528	A1	19970417	WO 1996-DK437	19961011
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC				
CA 2231273	AA	19970417	CA 1996-2231273	19961011
AU 9672792	A1	19970430	AU 1996-72792	19961011
AU 702030	B2	19990211		
EP 871489	A1	19981021	EP 1996-934441	19961011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11513393	T2	19991116	JP 1996-514651	19961011
NO 9801633	A	19980604	NO 1998-1633	19980408
FI 9800822	A	19980409	FI 1998-822	19980409
PRIORITY APPLN. INFO.:			DK 1995-1150	19951012

AB Pharmaceutical **compns.** for administration of an active substance to or through a damaged or undamaged skin or mucosal surface or to the oral cavity including the teeth of an animal such as a human. The **compn.** has advantageous properties with respect to release of the active substance from the **compn.** and, furthermore, the **compn.** is bioadhesive. The **compn.** comprises the active substance and an effective amt. of a fatty acid ester which, together with a liq. phase, is capable of generating a liq. cryst. phase in which the constituents of the **compn.** are enclosed, the active substance having a soly. in the liq. cryst. phase of at most 20 mg/g at 20.degree.C, and a soly. in water of at most 10 mg/mL at 20.degree.C, the water, where applicable, being buffered to a pH substantially identical to the pH prevailing in the liq. cryst. phase (pH about 3.6-9). The **compn.** is particularly suited for administration of substances which have a very low water soly. and which are to be supplied in an effective amt. in a localized region over a period of time. Active substances of particular importance are antiherpes virus agents including antiviral drugs and prodrugs thereof, such as nucleosides, nucleoside analogs, phosphorylated nucleosides (nucleotides), nucleotide analogs and salts, complexes and prodrugs thereof; e.g. guanosine analogs, deoxyguanosine analogs, guanine, guanine analogs, thymidine analogs, uracil analogs and adenine analogs. Esp. interesting antiherpes virus agents for use either alone or in combination in a **compn.** according to the present invention are selected from **acyclovir**, **famciclovir**, **desciclovir**, **penciclovir**, **zidovudine**, **ganciclovir**, **didanosine**, **zalcitabine**, **valaciclovir**, **sorivudine**, **lobucavir**, **brivudine**, **cidofovir**, **n-docosanol**, **ISIS-2922**, and prodrugs and analogs thereof.

L42 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:168557 CAPLUS  
 DOCUMENT NUMBER: 126:162277  
 TITLE: Pharmaceutical **composition** comprising an active agent dissolved in a glass-forming carrier  
 INVENTOR(S): Lindahl, Aake  
 PATENT ASSIGNEE(S): Bioglan Ab, Swed.; Lindahl, Aake  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700670	A1	19970109	WO 1996-SE806	19960619
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
CA 2225286	AA	19970109	CA 1996-2225286	19960619
AU 9662473	A1	19970122	AU 1996-62473	19960619
AU 695622	B2	19980820		
EP 833611	A1	19980408	EP 1996-921197	19960619
EP 833611	B1	20010822		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 11508250	T2	19990721	JP 1996-503789	19960619
AT 204466	E	20010915	AT 1996-921197	19960619
ES 2118677	T3	20011016	ES 1996-921197	19960619
ZA 9605237	A	19970109	ZA 1996-5237	19960620
US 6083518	A	20000704	US 1997-973902	19971217

HK 1008774 A1 20020328 HK 1998-109537 19980729  
 PRIORITY APPLN. INFO.: SE 1995-2244 A 19950620  
 WO 1996-SE806 W 19960619

AB A biol. active **compn.** comprising a soln. of an active agent dissolved in a glass-forming carrier, which carrier comprises a glass-forming substance contg. a plasticizer, the amt. of plasticizer preferably being selected so that the **compn.** has a non-solid consistency. The **compn.** can be prepd. by dissolving the active agent in a melted mixt. of the glass-forming substance and the plasticizer at a temp. below the decompn. temp. of said active agent. Thus, 4 g of citric acid was melted together with 5.5 g of propylene glycol at 110.degree. under stirring, the temp. was then lowered to 80.degree. and 0.5 g of **acyclovir** (I) was added. After the dissoln. of I, the temp. was lowered to room temp. The amt. of I after application on the human skin was .apprx.10 time higher than after application of a com. product.

L42 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:71430 CAPLUS  
 DOCUMENT NUMBER: 124:155977  
 TITLE: Cyclodextrin complexation  
 INVENTOR(S): Loftsson, Thorsteinn  
 PATENT ASSIGNEE(S): Cyclops h.f., Iceland  
 SOURCE: U.S., 31 pp. Cont.-in-part of U.S. 5,324,718.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5472954	A	19951205	US 1994-240510	19940511
US 5324718	A	19940628	US 1992-912853	19920714
EP 579435	A1	19940119	EP 1993-305280	19930706
EP 579435	B1	19990317		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 PRIORITY APPLN. INFO.: US 1992-912853 19920714  
 EP 1993-305280 19930706

AB The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile active ingredient which is a drug, cosmetic additive, food additive or agrochem., comprising combining from about 0.1 to about 70% (wt./vol.) of a cyclodextrin, from about 0.001 to about 5% (wt./vol.) of a pharmacol. inactive water-sol. polymer acceptable for use in a pharmaceutical, cosmetic, food or agricultural **compn.**, and said lipophilic and/or water-labile active ingredient in an aq. medium, the polymer and cyclodextrin being dissolved in the aq. medium before the active ingredient is added, the aq. medium which comprises the polymer and cyclodextrin being maintained at 30-150.degree. for 0.1-100 h before, during and/or after the active ingredient is added, optionally followed by removal of water. Related methods, co-complexes of active ingredient/cyclodextrin/polymer, pharmaceutical, cosmetic, food and agricultural **compns.** and cyclodextrin/polymer complexing agents are also provided.

L42 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:988109 CAPLUS  
 DOCUMENT NUMBER: 124:37704  
 TITLE: Use of fatty acid esters as bioadhesive substances  
 INVENTOR(S): Hansen, Jens; Sylvest Nielsen, Lise; Norling, Tomas  
 PATENT ASSIGNEE(S): A/S Dumex, Den.  
 SOURCE: PCT Int. Appl., 117 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526715	A2	19951012	WO 1995-DK143	19950329
WO 9526715	A3	19951116		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2186750	AA	19951012	CA 1995-2186750	19950329
AU 9522550	A1	19951023	AU 1995-22550	19950329
AU 685262	B2	19980115		
EP 752855	A1	19970115	EP 1995-915817	19950329
EP 752855	B1	19990609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09510980	T2	19971104	JP 1995-525360	19950329
AT 180971	E	19990615	AT 1995-915817	19950329
ES 2135723	T3	19991101	ES 1995-915817	19950329
FI 9603867	A	19961127	FI 1996-3867	19960927
NO 9604113	A	19961127	NO 1996-4113	19960927
PRIORITY APPLN. INFO.:			DK 1994-370	A 19940330
			WO 1995-DK143	W 19950329

AB The fatty acid esters as bioadhesive substances have mol. wts. < 1000 dalton and the fatty acid component of the fatty acid ester is a satd. or unsatd. fatty acid having a total no. of carbon atoms of C8-22. Particularly suitable fatty acid esters for use according to the invention are esters of polyhydric alcs., hydroxycarboxylic acids, **monosaccharides**, glycerylphosphate derivs., glycerylsulfate deriv., and mixts. thereof. Excellent bioadhesive properties have been obsd. for fatty acid esters of glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate. Methods are described for administering an active or protective substance to undamaged or damaged skin or mucosa of an animal such as a human by combining the active or protective substance with a bioadhesive fatty acid ester. The mucosa may be the oral, aural, nasal, lung, gastrointestinal, vaginal, or rectal mucosa. The administration may also be to body cavities such as the oral cavity, e.g. via buccal administration. Glyceryl monooleate (GMO) 48 was mixed with ethanol 32 and lidocaine-HCl 20 g, resp., and tested for bioadhesiveness. A residual amt. of .apprx.71% wt./wt. GMO was found after testing.

L42 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1994:253358 CAPLUS  
DOCUMENT NUMBER: 120:253358  
TITLE: Cyclodextrin complexes with polymers, drugs, agrochemicals and cosmetics  
INVENTOR(S): Loftsson, Thorsteinn  
PATENT ASSIGNEE(S): Iceland  
SOURCE: Eur. Pat. Appl., 46 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 579435	A1	19940119	EP 1993-305280	19930706
EP 579435	B1	19990317		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

US 5324718	A	19940628	US 1992-912853	19920714
AT 177647	E	19990415	AT 1993-305280	19930706
ES 2132190	T3	19990816	ES 1993-305280	19930706
US 5472954	A	19951205	US 1994-240510	19940511

PRIORITY APPLN. INFO.: US 1992-912853 19920714  
EP 1993-305280 19930706

AB A method for enhancing the complexation of a cyclodextrin (I) with a lipophilic and/or water-labile drug, comprising combining .apprx.0.1-70% (wt./vol.) of I and .apprx.0.001-5% (wt./vol.) of a water-sol. polymer in an aq. medium. The polymer and I are dissolved in the aq. medium before the drug is added. To a soln. contg. Na CM-cellulose 0.25 and 2-hydroxypropyl-.beta.-cyclodextrin 10% was added acetazolamide (II) and the soln. was heated at 120.degree. for 20 min and allowed to equilibrate at room temp. for 3 days and amt. of II was detd. The soly. of II was 3.11mg/mL as compared to 0.7 for control contg. only II. Different formulations contg. cyclodextrin complexes with polymers and drugs are disclosed.

L42 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:45751 CAPLUS  
DOCUMENT NUMBER: 118:45751  
TITLE: Use of combinations of gelling **polysaccharides** and finely divided drug carrier substrates in topical ophthalmic **compositions**  
INVENTOR(S): Missel, Paul Joseph Tracy; Jani, Rajni; Lang, John C.  
PATENT ASSIGNEE(S): Alcon Laboratories Inc., USA  
SOURCE: Eur. Pat. Appl., 28 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 507224	A2	19921007	EP 1992-105334	19920327
EP 507224	A3	19921028		
EP 507224	B1	19961030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
US 5212162	A	19930518	US 1992-857673	19920325
CA 2064160	AA	19920928	CA 1992-2064160	19920326
CA 2064160	C	19980811		
JP 07010776	A2	19950113	JP 1992-98596	19920326
JP 2536806	B2	19960925		
AU 9213863	A1	19921001	AU 1992-13863	19920327
AU 654175	B2	19941027		
AT 144701	E	19961115	AT 1992-105334	19920327
ES 2095975	T3	19970301	ES 1992-105334	19920327

PRIORITY APPLN. INFO.: US 1991-676146 19910327

AB Topical sustained-release ophthalmic **compns.** comprise gelling **polysaccharides** and finely-divided drug carrier substrates, such as ion-exchange resins. The **compn.**, without the drug, may be used to lubricate the eye or to supplement tears. A formulation (pH 7.4) comprised Eucheuma carrageenan 2.0, S-betaxolol 0.5, Na2HPO4 0.1, mannitol 3.5, Amberlite IRP-69 5.0, and water to 100% wt./vol.

L42 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1991:566639 CAPLUS  
DOCUMENT NUMBER: 115:166639  
TITLE: Preparation of slow-release oral pharmaceuticals, especially containing aspirin  
INVENTOR(S): Perovitch, Philippe  
PATENT ASSIGNEE(S): Futur-Quotidien S. A., Fr.

SOURCE: Fr. Demande, 41 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2649611	A1	19910118	FR 1989-9490	19890713
EP 468121	A1	19920129	EP 1990-402150	19900726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 494297	A1	19920715	EP 1991-914274	19910725
EP 494297	B1	19951018		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRIORITY APPLN. INFO.:			FR 1989-9490	19890713
			EP 1990-402150	19900726
			WO 1991-FR619	19910725

AB A slow-release pharmaceutical **compn.** is prepd. by (1) impregnating a support with solubilized active agent(s), (2) evapg. the solvent so that microparticles or microcrystals of the drug(s) form, and (3) submitting the product to appropriate conditioning. A hydrophilic polymer and a buffering substance may be added before step 3. Aspirin was dissolved in EtOH; sorbitol particles were impregnated with the soln.; and the EtOH was evapd. off, leaving small, uniformly integrated crystals of aspirin in the sorbitol support.

=> d his

(FILE 'HOME' ENTERED AT 09:04:21 ON 27 JUL 2003)

FILE 'CAPLUS' ENTERED AT 09:04:29 ON 27 JUL 2003

```

L1      0 S CARBOHYDRATES FOR FACILITATING THE TRANSPOR?
L2      0 S CARBOHYDRATES FOR ENHANC? THE TRANSPOR?
L3      2 S CARBOHYDRATES FOR ENHANC? THE ABSORPTION
L4      5 S ?SACCHARID? FOR ENHANC? THE ABSORPTION
L5      3 S ?SACCHARID? FOR PROMOT? THE ABSORPTION
L6      0 S ?SACCHARID? W ABSORPTION
L7      0 S ?SACCHARID? W6 ABSORPTION
L8      0 S ?SACCHARID? ADJ6 ABSORPTION
L9      0 S ?SACCHARID? ADJ6 ABSORPTION ADJ6 AMINO ACID?
L10     0 S ?CARBOHYDRAT? ADJ6 ABSORPTION ADJ6 AMINO ACID?
L11     0 S CARBOHYDRAT? ADJ6 ABSORPTION ADJ6 AMINO ACID?
L12     0 S CARBOHYDRAT? ABSORPTION AMINO ACID?
L13     0 S ?SACCHARID? FOR ENHANC? THE TRANSPOR?
L14     0 S ?SACCHARID? FOR INCREAS? THE TRANSPOR?
L15     0 S ?SACCHARID? INCREAS? THE TRANSPOR?
L16     3 S ?SACCHARID? INCREAS? THE ABSORPTION?
L17     3 S CARBOYDRAT? AND AMINO ACI?
L18     31 S CARBOYDRAT?
L19     183232 S CARBOHYDRAT?
L20     24450 S L19 AND AMINO ACI?
L21     8387 S L20 AND COMPOSITION
L22     2 S L21 AND TREATING DISORD?
L23     0 S L21 AND TREATING ADJ4 DISORD?
L24     80 S L21 AND TREATING
L25     0 S L24 AND EPITHEL?
L26     4 S L24 AND GASTRO?
L27     34 S L24 AND DISEAS?
L28     0 S ENHANCING AMINO ACID DELIVERY
L29     0 S ENHANCING AMINO ACIDS DELIVERY
L30     0 S FACILIT? AMINO ACIDS DELIVERY
L31     0 S ENHANCING AMINO ACIDS TRANSPOR?

```

L32	0	S	ENHANC?	AMINO	ACIDS	TRANSPOR?
L33	0	S	IMPROV?	AMINO	ACIDS	TRANSPOR?
L34	0	S	INCREAS?	AMINO	ACIDS	TRANSPOR?
L35	27	S	INCREAS?	AMINO	ACID	TRANSPOR?
L36	1	S	L35	AND	CARBOHYDRAT?	
L37	0	S	L35	AND	?SACCHARID?	
L38	2856	S	ACYCLOVIR			
L39	40	S	L38	AND	CARBOHYDRAT?	
L40	59	S	L38	AND	?SACCHARIDE?	
L41	59	S	L38	AND	?SACCHARID?	
L42	27	S	L41	AND	COMPOSITION	

=>



L Number	Hits	Search Text	DB	Time stamp
1	37313	glutamine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:36
2	1295	glutamine and hyaluronic adj acid	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:38
3	872	(glutamine and hyaluronic adj acid) and physiological	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:39
4	0	(glutamine and hyaluronic adj acid) and physiological adj disorder	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:38
5	7	(glutamine and hyaluronic adj acid) and physiological adj disorders	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:38
6	494	(glutamine and hyaluronic adj acid) and disorder	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:40
7	414	((glutamine and hyaluronic adj acid) and disorder) and enhanc?	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:40
8	371	((glutamine and hyaluronic adj acid) and disorder) and enhanc?) and cells	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:41
9	203	((glutamine and hyaluronic adj acid) and disorder) and enhanc?) and absorption	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:47
10	126496	amino adj acids	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:47
11	17964	(amino adj acids) and carbohydrates	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:48
12	58	((amino adj acids) and carbohydrates) and absorption adj promoters	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:00
13	29	((amino adj acids) and carbohydrates) and absorption adj promoters) and disorders	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:57
14	29	((amino adj acids) and carbohydrates) and absorption adj promoters) NOT (((amino adj acids) and carbohydrates) and absorption adj promoters) and disorders)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 07:57
15	49	((amino adj acids) and carbohydrates) and absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:07
16	0	carboydrates near4 absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:07
17	0	carboydrates near6 absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:07

18	0	carboydrates near8 absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:08
19	0	?saccharides near4 absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:08
20	0	?saccharides near8 absorption adj enhancers	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:08
21	0	?saccharides near8 absorption adj promoters	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:08
22	0	?saccharides near8 absorption adj promoters	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:09
23	0	carbohydrate? near8 absorption adj promoters	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:09
24	0	carbohydrate? near8 absorption adj promot?	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/27 08:09